The Oxford Handbook of Opioids and Opioid Use Disorder
Herausgeber: Dunn, Kelly E
The Oxford Handbook of Opioids and Opioid Use Disorder
Herausgeber: Dunn, Kelly E
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
The Oxford Handbook of Opioids and Opioid Use Disorder synthesizes research across the spectrum and establishes a foundational knowledge regarding historical and current epidemiological trends, neurobiological and genetic contributors to opioid effects and opioid use disorder (OUD), and core elements of opioid use such as withdrawal and craving. It also provides specific information and guidance regarding opioid treatment paradigms. This handbook will serve as a comprehensive guide for practitioners, policymakers, students, and researchers who wish to achieve a better understanding of the complex world of opioid and OUD practice and science.…mehr
Andere Kunden interessierten sich auch für
- The Oxford Handbook of Nonsuicidal Self-Injury280,99 €
- The Oxford Handbook of Early Childhood Learning and Development in Music261,99 €
- Mpia NdomboEducation of children living with dyslexia disorder57,99 €
- Amanda WebsterEmpowering Parents of Children with Autism Spectrum Disorder95,99 €
- Clarence Robert StoneSilent and Oral Reading: A Practical Handbook of Methods Based On the Most Recent Scientific Investigations39,99 €
- The Bloomsbury Handbook of Early Childhood Transitions Research226,99 €
- The Wiley Handbook of Early Childhood Care and Education234,99 €
-
-
-
The Oxford Handbook of Opioids and Opioid Use Disorder synthesizes research across the spectrum and establishes a foundational knowledge regarding historical and current epidemiological trends, neurobiological and genetic contributors to opioid effects and opioid use disorder (OUD), and core elements of opioid use such as withdrawal and craving. It also provides specific information and guidance regarding opioid treatment paradigms. This handbook will serve as a comprehensive guide for practitioners, policymakers, students, and researchers who wish to achieve a better understanding of the complex world of opioid and OUD practice and science.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Hurst & Co.
- Seitenzahl: 1072
- Erscheinungstermin: 21. Juni 2024
- Englisch
- Abmessung: 246mm x 175mm x 58mm
- Gewicht: 1905g
- ISBN-13: 9780197618431
- ISBN-10: 019761843X
- Artikelnr.: 67732661
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
- Verlag: Hurst & Co.
- Seitenzahl: 1072
- Erscheinungstermin: 21. Juni 2024
- Englisch
- Abmessung: 246mm x 175mm x 58mm
- Gewicht: 1905g
- ISBN-13: 9780197618431
- ISBN-10: 019761843X
- Artikelnr.: 67732661
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
Kelly E. Dunn, PhD, MBA, is Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University. Dunn has been working in the field of opioid use disorder since 2005, motivated by witnessing her community be ravaged with nonmedical use of prescription opioids as a teenager. This led to a passion for understanding motivations for opioid use, identifying methods to prevent the onset of opioid use disorder, improving treatments for opioid use disorder, and exploring new methods for managing pain and reducing opioid reliance. She has built a robust portfolio of laboratory and clinical trial research investigating these questions and is an author of more than 100 peer-reviewed publications in the area of substance use and opioid use disorder.
* Chapter 1: Historical Events that Shaped Contemporary Opioid Trends
* Kelly E. Dunn
* Chapter 2: Epidemiology of Opioid Use and Smoking, Alcohol, and
Polysubstance Use Among Persons Using Opioids
* Maria A. Parker and Whitney S. Cordoba-Grueso
* Chapter 3 Opioid Use Disorder: Diagnostic History and Current
Understanding
* Orrin D. Ware and Kelly E. Dunn
* Chapter 4: Access to Treatment for Opioid Use Disorder
* Brendan Saloner and Jason Gibbons
* Chapter 5: The Current Status of Medical Student Education on Opioids
* Oluwole Jegede, Peter J. Na, Ismene Petrakis, and Srinivas B. Muvvala
* Chapter 6: The Neurobiology of Opioid Use
* Shailesh N. Khatri, Erin E. Maher, Emma O. Bondy, and Cassandra D.
Gipson
* Chapter 7: Genetic Influences in Opioid Use Disorder
* Jill Rabinowitz and Brion Maher
* Chapter 8: The Opioid Withdrawal Syndrome: Presentation, Measurement,
and Management
* Kelly E. Dunn, Cecilia Bergeria, Orrin D. Ware, Eric C. Strain
* Chapter 9: Neonatal Abstinence Syndrome
* Sarah H. Heil, Heidi S. Melbostad, and Leigh-Anne Cioffredi
* Chapter 10: Opioid Craving: Understanding Its Measurement,
Mechanisms, and Treatment
* Cecilia Bergeria and Brandon Park
* Chapter 11: Opioids and Cognition
* Bethea A. Kleykamp, Shannon B. Clarke, and Shauna P. Acquavita
* Chapter 12: Opioid Effects on Sleep: Review of the Literature and
Consideration of the Hypothalamic-Pituitary-Adrenal Axis as a
Relevant Mechanism
* Jennifer D. Ellis, Chung Jung Mun, and Patrick H. Finan
* Chapter 13: Fentanyl
* Kelly E. Dunn, H. Elizabeth Bird, and Caitlyn J. Durgin
* Chapter 14: Tramadol
* Kelly E. Dunn, Judy Ashworth, and Eric C. Strain
* Chapter 15: Kratom (Mitragyna speciosa): Pharmacology and Use of a
Naturally Occurring Atypical Opioid
* Kirsten E. Smith, Oliver Grundmann, Marc T. Swogger, and Albert
Garcia-Romeu
* Chapter 16: Ibogaine and Noribogaine
* Deborah C. Mash and Michael Karukin
* Chapter 17: Abuse Deterrent and Sustained Release Opioid Formulations
* Rachel R. Luba, Sandra D. Comer, and Edward V. Nunes
* Chapter 18: Methadone
* Jonathan R. Buchholz, Molly Kalmoe, Justin Stamschror, and Andrew J.
Saxon
* Chapter 19: Buprenorphine
* Eric C. Strain and Andrew Gaddis
* Chapter 20: Naltrexone
* Marina Tsoy-Podosenin and Evgeny Krupitsky
* Chapter 21: Clonidine
* Mark S. Gold and Kenneth Blum
* Chapter 22: Lofexidine
* Charles W. Gorodetzky, Kristen L. Gullo, and Marc Fishman
* Chapter 23: Injectable Opioid Treatment
* Eugenia Oviedo-Joekes
* Chapter 24: Long-Term Treatment of Opioid Use Disorder With
Medications
* Aaron S. Wolfgang, Melissa B. Weimer, Peter J. Na, David A. Fiellin,
and Srinivas B. Muvvala
* Chapter 25: Supervised Withdrawal Opioid Use Disorder Treatments
* Kelly E. Dunn and Andrew S. Huhn
* Chapter 26: Psychosocial Treatment Methods
* Jessica M. Peirce, Denis G. Antoine, Alexis S. Hammond, and Michael
S. Kidorf
* Chapter 27: Behavioral and Self-directed Treatments for Opioid Use
Disorder
* Wendy Insalaco and J. Gregory Hobelmann
* Chapter 28: Contingency Management Treatment of Opioid Use Disorder
* August F. Holtyn, Forrest Toegel, and Matthew D. Novak
* Chapter 29: Treating Opioid Use During Pregnancy and Postpartum Life
Phases
* Hendrée E. Jones
* Chapter 30: Pharmacy-Based Treatment Options for Opioid Use Disorder
* Ali Cheetham and Suzanne Nielsen
* Chapter 31: Opioid Overdose: Mechanisms and Naloxone
* Jermaine D. Jones, Rachel R. Luba, Mudassir Mumtaz, and Felipe
Castillo
* Chapter 32: Opioid Overdose: Intervention Strategies
* Laura Brandt
* Chapter 33: Supervised Consumption Services
* Jeanette Bowles, Meaghan Thumath, Gillian Kolla, Zoe Dodd, Jaime
Arredondo Sanchez Lira, Frank Crichlow, and Leo Beletsky
* Chapter 34: Psychiatric Comorbidities Among Persons Who Are Using
Opioids
* R. Kathryn McHugh
* Chapter 35: Sex as a Biological Variable and Gender as a Social
Construct in the Treatment of Opioid Use Disorder
* Andrew S. Huhn
* Chapter 36: Challenges of Opioid Use Disorder in Rural Settings
* Stacey C. Sigmon and Jennifer R. Havens
* Chapter 37: Differences Between Those Engaged in Heroin Use and
Non-Prescribed Opioid Use
* Ty S. Schepis, Bowie Duncan, and Katherine Vrotsos
* Chapter 38: The Impact of Opioid Use Disorder on Families and
Children
* Erin L. Winstanley, Amanda Newhouse, and Kari-Beth Law
* Kelly E. Dunn
* Chapter 2: Epidemiology of Opioid Use and Smoking, Alcohol, and
Polysubstance Use Among Persons Using Opioids
* Maria A. Parker and Whitney S. Cordoba-Grueso
* Chapter 3 Opioid Use Disorder: Diagnostic History and Current
Understanding
* Orrin D. Ware and Kelly E. Dunn
* Chapter 4: Access to Treatment for Opioid Use Disorder
* Brendan Saloner and Jason Gibbons
* Chapter 5: The Current Status of Medical Student Education on Opioids
* Oluwole Jegede, Peter J. Na, Ismene Petrakis, and Srinivas B. Muvvala
* Chapter 6: The Neurobiology of Opioid Use
* Shailesh N. Khatri, Erin E. Maher, Emma O. Bondy, and Cassandra D.
Gipson
* Chapter 7: Genetic Influences in Opioid Use Disorder
* Jill Rabinowitz and Brion Maher
* Chapter 8: The Opioid Withdrawal Syndrome: Presentation, Measurement,
and Management
* Kelly E. Dunn, Cecilia Bergeria, Orrin D. Ware, Eric C. Strain
* Chapter 9: Neonatal Abstinence Syndrome
* Sarah H. Heil, Heidi S. Melbostad, and Leigh-Anne Cioffredi
* Chapter 10: Opioid Craving: Understanding Its Measurement,
Mechanisms, and Treatment
* Cecilia Bergeria and Brandon Park
* Chapter 11: Opioids and Cognition
* Bethea A. Kleykamp, Shannon B. Clarke, and Shauna P. Acquavita
* Chapter 12: Opioid Effects on Sleep: Review of the Literature and
Consideration of the Hypothalamic-Pituitary-Adrenal Axis as a
Relevant Mechanism
* Jennifer D. Ellis, Chung Jung Mun, and Patrick H. Finan
* Chapter 13: Fentanyl
* Kelly E. Dunn, H. Elizabeth Bird, and Caitlyn J. Durgin
* Chapter 14: Tramadol
* Kelly E. Dunn, Judy Ashworth, and Eric C. Strain
* Chapter 15: Kratom (Mitragyna speciosa): Pharmacology and Use of a
Naturally Occurring Atypical Opioid
* Kirsten E. Smith, Oliver Grundmann, Marc T. Swogger, and Albert
Garcia-Romeu
* Chapter 16: Ibogaine and Noribogaine
* Deborah C. Mash and Michael Karukin
* Chapter 17: Abuse Deterrent and Sustained Release Opioid Formulations
* Rachel R. Luba, Sandra D. Comer, and Edward V. Nunes
* Chapter 18: Methadone
* Jonathan R. Buchholz, Molly Kalmoe, Justin Stamschror, and Andrew J.
Saxon
* Chapter 19: Buprenorphine
* Eric C. Strain and Andrew Gaddis
* Chapter 20: Naltrexone
* Marina Tsoy-Podosenin and Evgeny Krupitsky
* Chapter 21: Clonidine
* Mark S. Gold and Kenneth Blum
* Chapter 22: Lofexidine
* Charles W. Gorodetzky, Kristen L. Gullo, and Marc Fishman
* Chapter 23: Injectable Opioid Treatment
* Eugenia Oviedo-Joekes
* Chapter 24: Long-Term Treatment of Opioid Use Disorder With
Medications
* Aaron S. Wolfgang, Melissa B. Weimer, Peter J. Na, David A. Fiellin,
and Srinivas B. Muvvala
* Chapter 25: Supervised Withdrawal Opioid Use Disorder Treatments
* Kelly E. Dunn and Andrew S. Huhn
* Chapter 26: Psychosocial Treatment Methods
* Jessica M. Peirce, Denis G. Antoine, Alexis S. Hammond, and Michael
S. Kidorf
* Chapter 27: Behavioral and Self-directed Treatments for Opioid Use
Disorder
* Wendy Insalaco and J. Gregory Hobelmann
* Chapter 28: Contingency Management Treatment of Opioid Use Disorder
* August F. Holtyn, Forrest Toegel, and Matthew D. Novak
* Chapter 29: Treating Opioid Use During Pregnancy and Postpartum Life
Phases
* Hendrée E. Jones
* Chapter 30: Pharmacy-Based Treatment Options for Opioid Use Disorder
* Ali Cheetham and Suzanne Nielsen
* Chapter 31: Opioid Overdose: Mechanisms and Naloxone
* Jermaine D. Jones, Rachel R. Luba, Mudassir Mumtaz, and Felipe
Castillo
* Chapter 32: Opioid Overdose: Intervention Strategies
* Laura Brandt
* Chapter 33: Supervised Consumption Services
* Jeanette Bowles, Meaghan Thumath, Gillian Kolla, Zoe Dodd, Jaime
Arredondo Sanchez Lira, Frank Crichlow, and Leo Beletsky
* Chapter 34: Psychiatric Comorbidities Among Persons Who Are Using
Opioids
* R. Kathryn McHugh
* Chapter 35: Sex as a Biological Variable and Gender as a Social
Construct in the Treatment of Opioid Use Disorder
* Andrew S. Huhn
* Chapter 36: Challenges of Opioid Use Disorder in Rural Settings
* Stacey C. Sigmon and Jennifer R. Havens
* Chapter 37: Differences Between Those Engaged in Heroin Use and
Non-Prescribed Opioid Use
* Ty S. Schepis, Bowie Duncan, and Katherine Vrotsos
* Chapter 38: The Impact of Opioid Use Disorder on Families and
Children
* Erin L. Winstanley, Amanda Newhouse, and Kari-Beth Law
* Chapter 1: Historical Events that Shaped Contemporary Opioid Trends
* Kelly E. Dunn
* Chapter 2: Epidemiology of Opioid Use and Smoking, Alcohol, and
Polysubstance Use Among Persons Using Opioids
* Maria A. Parker and Whitney S. Cordoba-Grueso
* Chapter 3 Opioid Use Disorder: Diagnostic History and Current
Understanding
* Orrin D. Ware and Kelly E. Dunn
* Chapter 4: Access to Treatment for Opioid Use Disorder
* Brendan Saloner and Jason Gibbons
* Chapter 5: The Current Status of Medical Student Education on Opioids
* Oluwole Jegede, Peter J. Na, Ismene Petrakis, and Srinivas B. Muvvala
* Chapter 6: The Neurobiology of Opioid Use
* Shailesh N. Khatri, Erin E. Maher, Emma O. Bondy, and Cassandra D.
Gipson
* Chapter 7: Genetic Influences in Opioid Use Disorder
* Jill Rabinowitz and Brion Maher
* Chapter 8: The Opioid Withdrawal Syndrome: Presentation, Measurement,
and Management
* Kelly E. Dunn, Cecilia Bergeria, Orrin D. Ware, Eric C. Strain
* Chapter 9: Neonatal Abstinence Syndrome
* Sarah H. Heil, Heidi S. Melbostad, and Leigh-Anne Cioffredi
* Chapter 10: Opioid Craving: Understanding Its Measurement,
Mechanisms, and Treatment
* Cecilia Bergeria and Brandon Park
* Chapter 11: Opioids and Cognition
* Bethea A. Kleykamp, Shannon B. Clarke, and Shauna P. Acquavita
* Chapter 12: Opioid Effects on Sleep: Review of the Literature and
Consideration of the Hypothalamic-Pituitary-Adrenal Axis as a
Relevant Mechanism
* Jennifer D. Ellis, Chung Jung Mun, and Patrick H. Finan
* Chapter 13: Fentanyl
* Kelly E. Dunn, H. Elizabeth Bird, and Caitlyn J. Durgin
* Chapter 14: Tramadol
* Kelly E. Dunn, Judy Ashworth, and Eric C. Strain
* Chapter 15: Kratom (Mitragyna speciosa): Pharmacology and Use of a
Naturally Occurring Atypical Opioid
* Kirsten E. Smith, Oliver Grundmann, Marc T. Swogger, and Albert
Garcia-Romeu
* Chapter 16: Ibogaine and Noribogaine
* Deborah C. Mash and Michael Karukin
* Chapter 17: Abuse Deterrent and Sustained Release Opioid Formulations
* Rachel R. Luba, Sandra D. Comer, and Edward V. Nunes
* Chapter 18: Methadone
* Jonathan R. Buchholz, Molly Kalmoe, Justin Stamschror, and Andrew J.
Saxon
* Chapter 19: Buprenorphine
* Eric C. Strain and Andrew Gaddis
* Chapter 20: Naltrexone
* Marina Tsoy-Podosenin and Evgeny Krupitsky
* Chapter 21: Clonidine
* Mark S. Gold and Kenneth Blum
* Chapter 22: Lofexidine
* Charles W. Gorodetzky, Kristen L. Gullo, and Marc Fishman
* Chapter 23: Injectable Opioid Treatment
* Eugenia Oviedo-Joekes
* Chapter 24: Long-Term Treatment of Opioid Use Disorder With
Medications
* Aaron S. Wolfgang, Melissa B. Weimer, Peter J. Na, David A. Fiellin,
and Srinivas B. Muvvala
* Chapter 25: Supervised Withdrawal Opioid Use Disorder Treatments
* Kelly E. Dunn and Andrew S. Huhn
* Chapter 26: Psychosocial Treatment Methods
* Jessica M. Peirce, Denis G. Antoine, Alexis S. Hammond, and Michael
S. Kidorf
* Chapter 27: Behavioral and Self-directed Treatments for Opioid Use
Disorder
* Wendy Insalaco and J. Gregory Hobelmann
* Chapter 28: Contingency Management Treatment of Opioid Use Disorder
* August F. Holtyn, Forrest Toegel, and Matthew D. Novak
* Chapter 29: Treating Opioid Use During Pregnancy and Postpartum Life
Phases
* Hendrée E. Jones
* Chapter 30: Pharmacy-Based Treatment Options for Opioid Use Disorder
* Ali Cheetham and Suzanne Nielsen
* Chapter 31: Opioid Overdose: Mechanisms and Naloxone
* Jermaine D. Jones, Rachel R. Luba, Mudassir Mumtaz, and Felipe
Castillo
* Chapter 32: Opioid Overdose: Intervention Strategies
* Laura Brandt
* Chapter 33: Supervised Consumption Services
* Jeanette Bowles, Meaghan Thumath, Gillian Kolla, Zoe Dodd, Jaime
Arredondo Sanchez Lira, Frank Crichlow, and Leo Beletsky
* Chapter 34: Psychiatric Comorbidities Among Persons Who Are Using
Opioids
* R. Kathryn McHugh
* Chapter 35: Sex as a Biological Variable and Gender as a Social
Construct in the Treatment of Opioid Use Disorder
* Andrew S. Huhn
* Chapter 36: Challenges of Opioid Use Disorder in Rural Settings
* Stacey C. Sigmon and Jennifer R. Havens
* Chapter 37: Differences Between Those Engaged in Heroin Use and
Non-Prescribed Opioid Use
* Ty S. Schepis, Bowie Duncan, and Katherine Vrotsos
* Chapter 38: The Impact of Opioid Use Disorder on Families and
Children
* Erin L. Winstanley, Amanda Newhouse, and Kari-Beth Law
* Kelly E. Dunn
* Chapter 2: Epidemiology of Opioid Use and Smoking, Alcohol, and
Polysubstance Use Among Persons Using Opioids
* Maria A. Parker and Whitney S. Cordoba-Grueso
* Chapter 3 Opioid Use Disorder: Diagnostic History and Current
Understanding
* Orrin D. Ware and Kelly E. Dunn
* Chapter 4: Access to Treatment for Opioid Use Disorder
* Brendan Saloner and Jason Gibbons
* Chapter 5: The Current Status of Medical Student Education on Opioids
* Oluwole Jegede, Peter J. Na, Ismene Petrakis, and Srinivas B. Muvvala
* Chapter 6: The Neurobiology of Opioid Use
* Shailesh N. Khatri, Erin E. Maher, Emma O. Bondy, and Cassandra D.
Gipson
* Chapter 7: Genetic Influences in Opioid Use Disorder
* Jill Rabinowitz and Brion Maher
* Chapter 8: The Opioid Withdrawal Syndrome: Presentation, Measurement,
and Management
* Kelly E. Dunn, Cecilia Bergeria, Orrin D. Ware, Eric C. Strain
* Chapter 9: Neonatal Abstinence Syndrome
* Sarah H. Heil, Heidi S. Melbostad, and Leigh-Anne Cioffredi
* Chapter 10: Opioid Craving: Understanding Its Measurement,
Mechanisms, and Treatment
* Cecilia Bergeria and Brandon Park
* Chapter 11: Opioids and Cognition
* Bethea A. Kleykamp, Shannon B. Clarke, and Shauna P. Acquavita
* Chapter 12: Opioid Effects on Sleep: Review of the Literature and
Consideration of the Hypothalamic-Pituitary-Adrenal Axis as a
Relevant Mechanism
* Jennifer D. Ellis, Chung Jung Mun, and Patrick H. Finan
* Chapter 13: Fentanyl
* Kelly E. Dunn, H. Elizabeth Bird, and Caitlyn J. Durgin
* Chapter 14: Tramadol
* Kelly E. Dunn, Judy Ashworth, and Eric C. Strain
* Chapter 15: Kratom (Mitragyna speciosa): Pharmacology and Use of a
Naturally Occurring Atypical Opioid
* Kirsten E. Smith, Oliver Grundmann, Marc T. Swogger, and Albert
Garcia-Romeu
* Chapter 16: Ibogaine and Noribogaine
* Deborah C. Mash and Michael Karukin
* Chapter 17: Abuse Deterrent and Sustained Release Opioid Formulations
* Rachel R. Luba, Sandra D. Comer, and Edward V. Nunes
* Chapter 18: Methadone
* Jonathan R. Buchholz, Molly Kalmoe, Justin Stamschror, and Andrew J.
Saxon
* Chapter 19: Buprenorphine
* Eric C. Strain and Andrew Gaddis
* Chapter 20: Naltrexone
* Marina Tsoy-Podosenin and Evgeny Krupitsky
* Chapter 21: Clonidine
* Mark S. Gold and Kenneth Blum
* Chapter 22: Lofexidine
* Charles W. Gorodetzky, Kristen L. Gullo, and Marc Fishman
* Chapter 23: Injectable Opioid Treatment
* Eugenia Oviedo-Joekes
* Chapter 24: Long-Term Treatment of Opioid Use Disorder With
Medications
* Aaron S. Wolfgang, Melissa B. Weimer, Peter J. Na, David A. Fiellin,
and Srinivas B. Muvvala
* Chapter 25: Supervised Withdrawal Opioid Use Disorder Treatments
* Kelly E. Dunn and Andrew S. Huhn
* Chapter 26: Psychosocial Treatment Methods
* Jessica M. Peirce, Denis G. Antoine, Alexis S. Hammond, and Michael
S. Kidorf
* Chapter 27: Behavioral and Self-directed Treatments for Opioid Use
Disorder
* Wendy Insalaco and J. Gregory Hobelmann
* Chapter 28: Contingency Management Treatment of Opioid Use Disorder
* August F. Holtyn, Forrest Toegel, and Matthew D. Novak
* Chapter 29: Treating Opioid Use During Pregnancy and Postpartum Life
Phases
* Hendrée E. Jones
* Chapter 30: Pharmacy-Based Treatment Options for Opioid Use Disorder
* Ali Cheetham and Suzanne Nielsen
* Chapter 31: Opioid Overdose: Mechanisms and Naloxone
* Jermaine D. Jones, Rachel R. Luba, Mudassir Mumtaz, and Felipe
Castillo
* Chapter 32: Opioid Overdose: Intervention Strategies
* Laura Brandt
* Chapter 33: Supervised Consumption Services
* Jeanette Bowles, Meaghan Thumath, Gillian Kolla, Zoe Dodd, Jaime
Arredondo Sanchez Lira, Frank Crichlow, and Leo Beletsky
* Chapter 34: Psychiatric Comorbidities Among Persons Who Are Using
Opioids
* R. Kathryn McHugh
* Chapter 35: Sex as a Biological Variable and Gender as a Social
Construct in the Treatment of Opioid Use Disorder
* Andrew S. Huhn
* Chapter 36: Challenges of Opioid Use Disorder in Rural Settings
* Stacey C. Sigmon and Jennifer R. Havens
* Chapter 37: Differences Between Those Engaged in Heroin Use and
Non-Prescribed Opioid Use
* Ty S. Schepis, Bowie Duncan, and Katherine Vrotsos
* Chapter 38: The Impact of Opioid Use Disorder on Families and
Children
* Erin L. Winstanley, Amanda Newhouse, and Kari-Beth Law